Stakeholder views regarding ethical issues in the design and conduct of pragmatic trials: study protocol

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 24 Nov 2018 )

Study protocol
Stakeholder views regarding ethical issues in the design and conduct of pragmatic trials: study protocol
Randomized controlled trial (RCT) trial designs exist on an explanatory-pragmatic spectrum, depending on the degree to which a study aims to address a question of efficacy or effectiveness. As conceptualized b…
Authors: Stuart G. Nicholls, Kelly Carroll, Jamie Brehaut, Charles Weijer, Spencer Phillips Hey, Cory E. Goldstein, Merrick Zwarenstein, Ian D. Graham, Joanne E. McKenzie, Lauralyn McIntyre, Vipul Jairath, Marion K. Campbell, Jeremy M. Grimshaw, Dean A. Fergusson and Monica Taljaard
Citation: BMC Medical Ethics 2018 19:90
Published on: 20 November 2018
Background
Randomized controlled trial (RCT) trial designs exist on an explanatory-pragmatic spectrum, depending on the degree to which a study aims to address a question of efficacy or effectiveness. As conceptualized by Schwartz and Lellouch in 1967, an explanatory approach to trial design emphasizes hypothesis testing about the mechanisms of action of treatments under ideal conditions (efficacy), whereas a pragmatic approach emphasizes testing effectiveness of two or more available treatments in real-world conditions. Interest in, and the number of, pragmatic trials has grown substantially in recent years, with increased recognition by funders and stakeholders worldwide of the need for credible evidence to inform clinical decision-making. This increase has been accompanied by the onset of learning healthcare systems, as well as an increasing focus on patient-oriented research. However, pragmatic trials have ethical challenges that have not yet been identified or adequately characterized. The present study aims to explore the views of key stakeholders with respect to ethical issues raised by the design and conduct of pragmatic trials. It is embedded within a large, four-year project that seeks to develop guidance for the ethical design and conduct of pragmatic trials. As a first step, this study will address important gaps in the current empirical literature with respect to identifying a comprehensive range of ethical issues arising from the design and conduct of pragmatic trials. By opening up a broad range of topics for consideration within our parallel ethical analysis, we will extend the current debate, which has largely emphasized issues of consent, to the range of ethical considerations that may flow from specific design choices.

Early life immunity in the era of systems biology: understanding development and disease

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 24 Nov 2018]

Comment
Early life immunity in the era of systems biology: understanding development and disease
Authors: Steven Schaffert and Purvesh Khatri
Citation: Genome Medicine 2018 10:88
Published on: 23 November 2018
Editorial summary
Systems immunology has the potential to offer invaluable insights into the development of the immune system. Two recent studies offer an in-depth view of both the dynamics of immune system development and the heritability of the levels of key immune modulators at birth.

Acquired mechanisms of immune escape in cancer following immunotherapy

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 24 Nov 2018]

Comment
Acquired mechanisms of immune escape in cancer following immunotherapy
Authors: J. Bryan Iorgulescu, David Braun, Giacomo Oliveira, Derin B. Keskin and Catherine J. Wu
Citation: Genome Medicine 2018 10:87
Published on: 22 November 2018
Abstract
Immunotherapy has revolutionized the management of numerous cancers; however, a substantial proportion that initially respond subsequently acquire means of immune escape and relapse. Analysis of recent clinical trials permits us to preliminarily understand how immunotherapies exert evolutionary pressures: selecting cancer subclones deficient in antigenicity and/or immunogenicity, thereby facilitating immune escape.

 

Toward a global health approach: lessons from the HIV and Ebola epidemics

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 24 Nov 2018 ]

Commentary
Toward a global health approach: lessons from the HIV and Ebola epidemics
The imposing burden of non-communicable diseases, emerging infectious diseases, climate change, environmental consequences, migrations, urbanization, and other challenges, faced in a context that strives to make universal health coverage (UHC) a reality, compels global health professionals to ask: how do we construct a “global” roadmap that is both realistic and effective? To move forward and begin to answer this question, we draw on lessons and experiences gained during the “global” health crises triggered by the HIV and Ebola pandemics.
Authors: Gilles Raguin and Pierre-Marie Girard
Citation: Globalization and Health 2018 14:114
Published on: 22 November 2018

Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 24 Nov 2018 ]

Research
Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences
National pharmacovigilance centres (national centres) are gradually gaining visibility as part of the healthcare delivery system in Africa. As does happen in high-income countries, it is assumed that national centres can play a central coordinating role in their national pharmacovigilance (PV) systems. However, there are no studies that have investigated whether national centres in Africa have sufficient organizational capacity to deliver on this mandate and previous studies have reported challenges such as lack of funding, political will and adequate human resources.
We conducted interviews with strategic leaders in national centres in 18 African countries, to examine how they link the capacity of their organization to the outcomes of activities coordinated by their centres. Strategic leaders were asked to describe three situations in which activities conducted by their centre were deemed successful and unsuccessful. We analyzed these experiences for common themes and examined whether strategic leaders attributed particular types of resources and relationships with stakeholders to successful or unsuccessful activities.
Authors: H. Hilda Ampadu, Jarno Hoekman, Daniel Arhinful, Marilyn Amoama-Dapaah, Hubert G. M. Leufkens and Alex N. O. Dodoo
Citation: Globalization and Health 2018 14:109
Published on: 16 November 2018
 

Rohingya refugees in Bangladesh: the humanitarian response

Humanitarian Exchange Magazine
Number 73,  October 2018
https://odihpn.org/magazine/mental-health-and-psychosocial-support-in-humanitarian-crises/

Rohingya refugees in Bangladesh: the humanitarian response

More than 700,000 Rohingya refugees have arrived in Bangladesh since 25 August 2017 fleeing violence and persecution in Rakhine State, Myanmar. Over a million are sheltering in overcrowded camps without adequate assistance or protection. Stateless in Myanmar and denied refugee status in Bangladesh, the Rohingya have few rights or freedoms. Monsoons and cyclones are causing landslides, destroying shelters and infrastructure and disrupting services.

This edition of Humanitarian Exchange focuses on the humanitarian response to the Rohingya crisis. In the lead article, Mark Bowden outlines the historical, local and national political context in Bangladesh, and its operational implications. Amal de Chickera highlights the links between statelessness and displacement, and the international community’s failure to prioritise human rights in its dealings both with Bangladesh and with Myanmar. Puttanee Kangkun and John Quinley document the persistent persecution and denial of rights the Rohingya have faced for decades. Jeff Crisp reflects on the premature, involuntary and unsafe return of Rohingya refugees to Myanmar in the 1970s and 1990s, and asks whether this could happen again.

Sally Shevach and colleagues explore how the ‘localisation’ agenda has influenced the operational response, and Kerrie Holloway draws on research by the Humanitarian Policy Group to test the common assumption that local actors necessarily have a better understanding of people’s needs. Nasif Rashad Khan and colleagues and Ashish Banik reflect on their experiences of engaging with the international humanitarian response system. Margie Buchanan-Smith and Marian Casey-Maslen discuss evaluation findings relating to communication and community engagement, a theme taken up by Nick Van Praag and Kai Hopkins, who report on a Ground Truth survey on refugees’ perceptions of assistance. Julia Brothwell discusses the British Red Cross/Bangladesh Red Crescent involvement in disaster preparedness and risk reduction during the monsoon season, and Gina Bark, Kate White and Amelie Janon outline the consequences of long-term exclusion from basic healthcare services in increasing vulnerability to preventable diseases. Matthew Wencel and colleagues round off the issue with reflections on data collection coordination and other challenges associated with monitoring large concentrations of refugees.

Knowledge, Attitudes and Barriers to Human Papillomavirus (HPV) Vaccine Uptake Among an Immigrant and Refugee Catch-Up Group in a Western Canadian Province

Journal of Immigrant and Minority Health
Volume 20, Issue 6, December 2018
https://link.springer.com/journal/10903/20/6/page/1

Original Paper
Knowledge, Attitudes and Barriers to Human Papillomavirus (HPV) Vaccine Uptake Among an Immigrant and Refugee Catch-Up Group in a Western Canadian Province
Erin McComb, Vivian Ramsden

Knowledge, Attitudes and Barriers to Human Papillomavirus (HPV) Vaccine Uptake Among an Immigrant and Refugee Catch-Up Group in a Western Canadian Province

Journal of Immigrant and Minority Health
Volume 20, Issue 6, December 2018
https://link.springer.com/journal/10903/20/6/page/1

Original Paper
Knowledge, Attitudes and Barriers to Human Papillomavirus (HPV) Vaccine Uptake Among an Immigrant and Refugee Catch-Up Group in a Western Canadian Province
Erin McComb, Vivian Ramsden

Improved reference genome of Aedes aegypti informs arbovirus vector control

Nature 
Volume 563 Issue 7732, 22 November 2018
http://www.nature.com/nature/current_issue.html

Article | 14 November 2018 | open
Improved reference genome of Aedes aegypti informs arbovirus vector control
An improved, fully re-annotated Aedes aegypti genome assembly (AaegL5) provides insights into the sex-determining M locus, chemosensory systems that help mosquitoes to hunt humans and loci involved in insecticide resistance and will help to generate intervention strategies to fight this deadly disease vector.
Benjamin J. Matthews, Olga Dudchenko […]  & Leslie B. Vosshall

Improved reference genome of Aedes aegypti informs arbovirus vector control

Nature 
Volume 563 Issue 7732, 22 November 2018
http://www.nature.com/nature/current_issue.html

Article | 14 November 2018 | open
Improved reference genome of Aedes aegypti informs arbovirus vector control
An improved, fully re-annotated Aedes aegypti genome assembly (AaegL5) provides insights into the sex-determining M locus, chemosensory systems that help mosquitoes to hunt humans and loci involved in insecticide resistance and will help to generate intervention strategies to fight this deadly disease vector.
Benjamin J. Matthews, Olga Dudchenko […]  & Leslie B. Vosshall

New Tools in the Ebola Arsenal

New England Journal of Medicine
November 22, 2018  Vol. 379 No. 21
http://www.nejm.org/toc/nejm/medical-journal

Perspective
New Tools in the Ebola Arsenal
Inger K. Damon, M.D., Ph.D., Pierre E. Rollin, M.D., Mary J. Choi, M.D., M.P.H., Ray R. Arthur, Ph.D., and Robert R. Redfield, M.D.
… Although investigational therapeutics were not used in the previous outbreak in Equateur, some experts believe that the investigational protocol to enable use of vaccines for evaluation of protection of patients’ contacts and those contacts’ contacts may have facilitated engagement of affected communities. Final data on the effectiveness of the vaccination program in Equateur is not yet available. In North Kivu, the recombinant VSV-Ebola glycoprotein vaccine is currently being used under an expanded-access protocol to vaccinate patients’ contacts and their contacts, to provide a ring of vaccine-elicited protection, as well as for at-risk front-line workers and health care workers. As of September 25, more than 12,029 people had been vaccinated. Understanding community concerns and attitudes about the use of investigational agents will be critical if the use of these treatments is to be integrated into response efforts…
As of September 23, investigational agents had been administered to 38 patients — MAb114 (22), remdesivir (9), and ZMapp (7). Nineteen of these patients had been discharged, 12 had died, and 7 had remained hospitalized; those who died were in advanced stages of disease when treatment was initiated.4 Criteria such as viral load (at presentation and throughout treatment) and interval between disease onset and treatment will need to be analyzed. One aspect that will be important to understand is how, or whether, these therapeutics affect clearance of virus from immune-privileged sites, such as the eye, and from seminal fluids…

Healthy volunteers’ perceptions of risk in US Phase I clinical trials: A mixed-methods study

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 24 Nov 2018 )

Research Article
Healthy volunteers’ perceptions of risk in US Phase I clinical trials: A mixed-methods study
Jill A. Fisher, Lisa McManus, Marci D. Cottingham, Julianne M. Kalbaugh, Megan M. Wood, Torin Monahan, Rebecca L. Walker
| published 20 Nov 2018 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1002698

‘Google wants to know your location’: The ethical challenges of fieldwork in the digital age

Research Ethics
Volume 14 Issue 4, October 2018
http://journals.sagepub.com/toc/reab/current

Topic Piece
‘Google wants to know your location’: The ethical challenges of fieldwork in the digital age
Sebastian van Baalen
First Published January 1, 2018; pp. 1–17
Preview
Information communications technologies (ICTs) like laptops, smartphones and portable storage devices facilitate travel, communication and documentation for researchers who conduct fieldwork. But despite increasing awareness about the ethical complications associated with using ICTs among journalists and humanitarians, there are few reflections on digital security among researchers. This article seeks to raise awareness of this important question by outlining three sets of ethical challenges related to digital security that may arise during the course of field research. These ethical challenges relate to (i) informed consent and confidentiality, (ii) collecting, transferring and storing sensitive data, and (iii) maintaining the personal security and integrity of the researcher. To help academics reflect on and mitigate these risks, the article underscores the importance of digital risk assessments and develops ten basic guidelines for field research in the digital age.

Ethics review and freedom of information requests in qualitative research

Research Ethics
Volume 14 Issue 4, October 2018
http://journals.sagepub.com/toc/reab/current

Original Article: Non-Empirical
Ethics review and freedom of information requests in qualitative research
Kevin Walby, Alex Luscombe
First Published January 1, 2018; pp. 1–15
Preview
Freedom of information (FOI) requests are increasingly used in sociology, criminology and other social science disciplines to examine government practices and processes. University ethical review boards (ERBs) in Canada have not typically subjected researchers’ FOI requests to independent review, although this may be changing in the United Kingdom and Australia, reflective of what Haggerty calls ‘ethics creep’. Here we present four arguments for why FOI requests in the social sciences should not be subject to formal ethical review by ERBs. These four arguments are: existing, rigorous bureaucratic vetting; double jeopardy; infringement of citizenship rights; and unsuitable ethics paradigm. In the discussion, we reflect on the implications of our analysis for literature on ethical review and qualitative research, and for literature on FOI and government transparency.

 

Is it time for a universal genetic forensic database?

Science         
23 November 2018  Vol 362, Issue 6417
http://www.sciencemag.org/current.dtl

Policy Forum
Is it time for a universal genetic forensic database?
By J. W. Hazel, E. W. Clayton, B. A. Malin, C. Slobogin
Science23 Nov 2018 : 898-900 Restricted Access
Bias and privacy concerns cloud police use of genetics
Summary
DNA is an increasingly useful crime-solving tool. But still quite unclear is the extent to which law enforcement should be able to obtain genetic data housed in public and private databases. How one answers that question might vary substantially, depending on the source of the data. Several countries—the United Kingdom, Kuwait, and Saudi Arabia among them—have even toyed with creating a “universal” DNA database, populated with data from every individual in society, obviating the need for any other DNA source (1). Although this move would be controversial, it may not be as dramatic as one might think. In the United States, for example, the combination of state and federal databases (containing genetic profiles of more than 16.5 million arrestees and convicts) and public and private databases (containing genetic data of tens of millions of patients, consumers, and research participants) already provides the government with potential access to genetic information that can be linked to a large segment of the country, either directly or through a relative (2, 3). We discuss here how, if correctly implemented, a universal database would likely be more productive and less discriminatory than our current system, without compromising as much privacy.

 

Preparing for safety monitoring after rotavirus vaccine introduction – Assessment of baseline epidemiology of intussusception among children <2 years of age in four Asian countries

Vaccine
Volume 36, Issue 50 Pages 7589-7754 (29 November 2018)
https://www.sciencedirect.com/science/article/pii/S0264410X18314683

Research article  Abstract only
Preparing for safety monitoring after rotavirus vaccine introduction – Assessment of baseline epidemiology of intussusception among children <2 years of age in four Asian countries
Eleanor Burnett, Nguyen Van Trang, Ajit Rayamajhi, Mohammad Tahir Yousafzai, … Umesh D. Parashar
Pages 7593-7598

Influenza and pertussis vaccination in pregnancy: Portrayal in online media articles and perceptions of pregnant women and healthcare professionals

Vaccine
Volume 36, Issue 50 Pages 7589-7754 (29 November 2018)
https://www.sciencedirect.com/science/article/pii/S0264410X18314683

Research article  Open access
Influenza and pertussis vaccination in pregnancy: Portrayal in online media articles and perceptions of pregnant women and healthcare professionals
Christopher R Wilcox, Kathryn Bottrell, Pauline Paterson, William S Schulz, … Christine E Jones
Pages 7625-7631

Estimating costs and health outcomes of publicly funded tick-born encephalitis vaccination: A cost-effectiveness analysis

Vaccine
Volume 36, Issue 50 Pages 7589-7754 (29 November 2018)
https://www.sciencedirect.com/science/article/pii/S0264410X18314683

Research article  Abstract only
Estimating costs and health outcomes of publicly funded tick-born encephalitis vaccination: A cost-effectiveness analysis
Jad Shedrawy, Martin Henriksson, Maria-Pia Hergens, H. Helena Askling
Pages 7659-7665

Social differentiation of vaccine hesitancy among French parents and the mediating role of trust and commitment to health: A nationwide cross-sectional study

Vaccine
Volume 36, Issue 50 Pages 7589-7754 (29 November 2018)
https://www.sciencedirect.com/science/article/pii/S0264410X18314683

Research article  Abstract only
Social differentiation of vaccine hesitancy among French parents and the mediating role of trust and commitment to health: A nationwide cross-sectional study
Aurélie Bocquier, Lisa Fressard, Sébastien Cortaredona, Anna Zaytseva, … Pierre Verger
Pages 7666-7673

Improving immunization data quality in Peru and Mexico: Two case studies highlighting challenges and lessons learned

Vaccine
Volume 36, Issue 50 Pages 7589-7754 (29 November 2018)
https://www.sciencedirect.com/science/article/pii/S0264410X18314683

Research article  Abstract only
Improving immunization data quality in Peru and Mexico: Two case studies highlighting challenges and lessons learned
Silas P. Trumbo, Marcela Contreras, Ana Gabriela Félix García, Fabio Alberto Escobar Díaz, … Martha Velandia-González
Pages 7674-7681

Fast Tracks and Roadblocks for Zika Vaccines

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines
(Accessed 24 Nov 2018 )

Open Access  Review
Fast Tracks and Roadblocks for Zika Vaccines
by Khairunnisa Abdul Ghaffar, Lisa F.P. Ng and Laurent Renia
Vaccines 2018, 6(4), 77; https://doi.org/10.3390/vaccines6040077 – 21 November 2018
Abstract
In early 2014, a relatively obscure virus, the Zika virus, made headlines worldwide following an increase in the number of congenital malformations. Since then, research on Zika virus, treatment and vaccines have progressed swiftly with various drugs being repurposed and vaccines heading into clinical trials. Nonetheless, the need for a vaccine is crucial in order to eradicate this re-emerging arthropod-borne virus which remained silent since its first discovery in 1947. In this review, we focused on how the inconspicuous virus managed to spread, the key immunological factors required for a vaccine and the various vaccine platforms that are currently being studied.

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Viruses
2018, 10(11), 648
Willingness to Participate and Associated Factors in a Zika Vaccine Trial in Indonesia: A Cross-Sectional Study
H Harapan, M Mudatsir, A Yufika, Y Nawawi… –
Abstract
One of the crucial steps during trials for Zika and other vaccines is to recruit participants and to understand how participants’ attitudes and sociodemographic characteristics affect willingness to participate (WTP). This study was conducted to assess WTP, its explanatory variables, and the impact of financial compensation on WTP in Indonesia. A health facility-based cross-sectional study was conducted in eleven regencies in the Aceh and West Sumatra provinces of Indonesia. Participants were recruited via a convenience sampling method and were interviewed. The associations between explanatory variables and WTP were assessed using a two-step logistic regression analysis. A total of 1,102 parents were approached, and of these 956 (86.8%) completed the interview and were included in analysis. Of those, 144 (15.1%) were willing to participate in a Zika vaccine trial without a financial compensation. In the multivariate analysis, WTP was tied to an age of more than 50 years old, compared to 20–29 years (odds ratio (OR): 5.0; 95% confidence interval (CI): 2.37–10.53), to being female (OR: 2.20; 95% CI: 1.11–4.37), and to having heard about Zika (OR: 2.41; 95% CI: 1.59–3.65). Participants’ WTP increased gradually with higher financial compensation. The rate of WTP increased to 62.3% at the highest offer (US$ 350.4), and those who were still unwilling to participate (37.7%) had a poorer attitude towards childhood vaccination. This study highlights that pre-existing knowledge about Zika and attitudes towards childhood vaccination are important in determining community members being willing to participate in a vaccine trial. Financial incentives are still an important factor to enhance participant recruitment during a vaccine trial.

PharmacoEconomics & Outcomes News
November 2018, Volume 816, Issue 1, pp 24–24
https://link.springer.com/journal/40274
Latest Articles
Pharmacist-administered influenza vaccinations save cost
DJ O’Reilly

Media/Policy Watch

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.
 
 
The Atlantic
http://www.theatlantic.com/magazine/
Accessed 24 Nov 2018  
[No new, unique, relevant content]
 
 
BBC
http://www.bbc.co.uk/
Accessed 24 Nov 2018  
19 Nov 2018
Anti-vaccine community behind North Carolina chickenpox outbreak
A North Carolina school with a large anti-vaccine community is at the heart of the state’s largest chickenpox outbreak in decades, officials say.
 
 
The Conversation
https://theconversation.com/us
Accessed 24 Nov 2018
3 ethical reasons for vaccinating your children
19 November 2018
…1. Failure to contribute to the public good: Public goods benefit everyone. Take the example of roads, clean drinking water or universal education. Public health – the health of the overall population as a result of society-wide policies and practices – also falls into this category. …

  1. Impact of health choices on the vulnerable: Viruses do not affect everyone equally. Oftentimes, it is the elderly, infants, and people with weakened immune systems, who are most at risk. …

3: Health is communal: … democratic public institutions necessarily rely upon belief in scientific evidence and facts. People can hold different personal beliefs, but there are some truths that are irrefutable, such as the fact that the Earth is round and revolves around the sun. Anti-science attitudes are dangerous because they undermine our ability to make decisions together as a society, whether about education, infrastructure or health…
 
 
The Economist
http://www.economist.com/
Accessed 24 Nov 2018  
[No new, unique, relevant content]
 
 
Financial Times
http://www.ft.com/home/uk
Accessed 24 Nov 2018  
[No new, unique, relevant content]
 
 
Forbes
http://www.forbes.com/
Accessed 24 Nov 2018
[No new, unique, relevant content]
 
 
Foreign Affairs
http://www.foreignaffairs.com/
Accessed 24 Nov 2018  
[No new, unique, relevant content]
 
 
Foreign Policy
http://foreignpolicy.com/
Accessed 24 Nov 2018  
[No new, unique, relevant content]
 
 
The Guardian
http://www.guardiannews.com/
Accessed 24 Nov 2018
Global health
Deadliest year for dengue fever in Bangladesh as cases explode in Dhaka
Cases more than triple in the capital driven by unplanned rapid urbanisation and poor healthcare
…. Singapore has also seen soaring numbers of dengue cases, which studies have linked to the city’s growing population and construction sites. The rise was followed by a swift response from the Singaporean government targeting such sites.
In Sri Lanka the government has created a special taskforce for dengue prevention. This includes monitoring where the larvae are found and exterminating them…
 
 
New Yorker
http://www.newyorker.com/
Accessed 24 Nov 2018
[No new, unique, relevant content]
 
 
New York Times
http://www.nytimes.com/
Accessed 24 Nov 2018
Sunday Review
Trying to Fight, Not Spread, Fear and Lies
How can the media avoid the misinformation trap?
Nov. 23, 2018
By Nicholas Kristof
 
Health
Ebola in Congo Now Infecting Newborn Babies, UN Says
The World Health Organization says a worrying number of the newest Ebola cases amid Congo’s ongoing outbreak are in patients not usually known to catch the disease: babies.
Nov. 23, 2018
 
 
 
Wall Street Journal
http://online.wsj.com/home-page?_wsjregion=na,us&_homepage=/home/us
Accessed 24 Nov 2018
[No new, unique, relevant content]
 
 
Washington Post
http://www.washingtonpost.com/
Accessed 24 Nov 2018
[No new, unique, relevant content]

Think Tanks et al

Think Tanks et al
 
 
Brookings
http://www.brookings.edu/
Accessed 24 Nov 2018
Future Development
We need a consensus on the definition of ‘global public goods for health’
Gavin Yamey, Osondu Ogbuoji, and Kaci Kennedy
Tuesday, November 20, 2018
 
 
Center for Global Development  
http://www.cgdev.org/page/press-center
Accessed 24 Nov 2018
[No new relevant content]
 
 
CSIS
https://www.csis.org/
Accessed 24 Nov 2018
[No new relevant content]
 
 
Council on Foreign Relations
http://www.cfr.org/
Accessed 24 Nov 2018
[No new relevant content]

Vaccines and Global Health: The Week in Review :: 17 November 2018

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_17 Nov 2018

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Global Task Force on Cholera Control marks a year of progress toward ending cholera worldwide

Milestones :: Perspectives

Global Task Force on Cholera Control marks a year of progress toward ending cholera worldwide

GENEVA/ NEW YORK, 30 October 2018 – This month, partners of the Global Task Force on Cholera Control (GTFCC) mark one year since the launch of Ending Cholera: A Global Roadmap to 2030, which targets a 90% reduction in cholera deaths by 2030 and the elimination of cholera in at least 20 countries out of the 47 currently affected.

At the 4 October 2017 launch of the Global Roadmap in Annecy, France, 35 global health and WASH organizations leading the fight against cholera signed the Declaration on Ending Cholera, committing their financial and human resources in support of its implementation in countries.

One year later, the movement to end cholera has made exceptional progress. At least 10 countries are now taking active measures towards cholera control plans in alignment with the Global Roadmap: Bangladesh, Haiti, Kenya, Malawi, Nigeria, South Sudan, Uganda, Zambia, the United Republic of Tanzania, and Zimbabwe. In addition, 47 African countries adopted the Regional Framework for the Implementation of the Global Strategy for Cholera Prevention and Control on 28 August at the 68th session of the WHO Regional Committee for Africa.

In May 2018, at the 71st World Health Assembly (WHA), WHO Member States took the extraordinary step of passing a resolution—introduced by the Governments of Zambia and Haiti—committing to implementation of the Global Roadmap, calling for the resources and policy changes necessary to meet the goal.

In line with the Global Roadmap, the Africa Regional Framework and the WHA resolution commit countries to implement evidence-based measures including:

:: mapping of cholera hotspots

:: significant investment in safe water, sanitation, and hygiene (WASH)

:: use of oral cholera vaccine

:: enhanced epidemiological and laboratory surveillance

:: improving access to timely treatment

:: promoting community engagement.

Cholera-affected countries demonstrate strong leadership and determination to stop cholera outbreaks

Examples include:

:: The end of the longest cholera outbreak in South Sudan in February 2018 shows it is possible to stop persistent cholera outbreaks in endemic settings, achieving high vaccine coverage even in the context of conflict and instability. The outbreak, which started in June 2016, resulted in 20,000 cases and 436 deaths. South Sudan conducted 38 vaccination campaigns, using a flexible data-driven approach to allocate 2.8 million doses to people living in hotspots as conditions made it possible to reach them.

:: Yemen, the location of the world’s most severe cholera outbreak, saw its first use of Oral Cholera Vaccine in 2018 – a critical step in fighting cholera there. Nearly 700,000 people have already been vaccinated and, another 1.4 million people are expected to receive vaccines in the coming weeks.  However, widespread malnutrition, and destruction of water and sanitation infrastructure will require additional efforts to bring cholera under control in Yemen.

Cholera-affected countries plan a future without cholera by developing multi-sectoral cholera control plans .

:: The Government of Zanzibar, a semi-autonomous part of the United Republic of Tanzania, is ready to the Zanzibar Comprehensive Cholera Elimination Plan (ZACCEP), a costed multi-sectoral cholera elimination plan in alignment with the Global Roadmap, which aims to end cholera by 2027.

The Government of Bangladesh revised its National Program on Diarrheal Diseases Prevention, Management & Control to align it with the Global Roadmap, working with national WASH partners to collectively implement a plan to target elimination by 2030. Introduction of a phased large scale OCV campaign is planned to start in 2019. Professor Abul Kalam Azad, Director General of Health Services, Ministry of Health & Family Welfare, noted that cholera has no place in a country like Bangladesh, which is striving toward middle-income status: “Bangladesh has made huge strides in health outcomes in recent years. It is now time to commit the resources to ensure cholera will no longer be a threat to the people of Bangladesh.”

The Government of Zambia is launching a national multi-sectoral plan, aligned with the Global Roadmap strategy, targeting elimination of cholera by 2025. The response to the October 2017 outbreak triggered strong political engagement. Honorable Chitalu Chilufya, Minister of Health, observed “the government of Zambia has provided exemplary leadership in halting last year’s outbreak, bringing together a well-resourced, multi-sectoral response. With this strong political will and a sound national plan, I am confident that Zambia will be free from cholera by 2025.”

Unprecedented use of Oral Cholera Vaccine in 2018, including the largest cholera vaccination drive in history

As countries voted to pass the WHA resolution, five countries were already preparing for the largest cholera vaccination drive in history. The oral cholera vaccines were sourced from the global stockpile, funded by Gavi, the Vaccine Alliance, for five major campaigns in Zambia, Uganda, Malawi, South Sudan and Nigeria. The campaign protected over two million people from the threat of cholera. UNICEF procured 15.2 million doses to 12 countries to date, on top of nearly 10 million doses delivered in 2017. This compares to just 200,000 doses delivered in 2013, when the stockpile was created. OCV is just one tool in a much larger toolbox that includes sustainable safe water, sanitation, and hygiene (WASH), but it serves as a critical bridge to these longer-term efforts.

An energized GTFCC partnership supports countries in the fight to #EndCholera

GTFCC partners are taking action on their commitment from October 2017, by aligning their programs with the Global Roadmap and by increasing resources to concretely support cholera control efforts. In partnership with WHO, UNICEF brings strong leadership to the GTFCC working group on Water Sanitation and Hygiene (WASH). In 2018, the International Federation of Red Cross and Red Crescent Societies (IFRC) launched the One WASH program, an integrated approach that will support more than 20 cholera-affected countries. Projects are already in start-up phase in Uganda, Ghana, Malawi and Rwanda with an initial commitment of US$2.5 million. The Wellcome Trust and the UK Department for International Development (DFID) issued a call for proposals to support the cholera research agenda. The US Centers for Disease Control and Prevention (CDC) is providing technical experts in-country upon request, which is a critical allocation of human and other resources in the fight against cholera.

Ministers agree on international action to address antimicrobial resistance in animals and to safeguard medicines for humans and animals alike

Ministers agree on international action to address antimicrobial resistance in animals and to safeguard medicines for humans and animals alike

Marrakesh, 31 October 2018 –  The World Organisation for Animal Health (OIE) hosted this week global leaders in animal health from the private and public sectors and civil society to discuss new ideas and solutions to the global rise of antimicrobial resistance (AMR). The three-day event was placed under the high patronage of his majesty Mohammed VI, King of Morocco. Entitled the 2nd Global Conference on Antimicrobial Resistance and Prudent Use of Antimicrobial Agents in Animals, it focussed on the role played by animal health in what is one of the 21st century’s starkest global health challenges.

Prevention of AMR in farming is critical to human health, as well as to food safety, food security, animal health and animal welfare. Antimicrobials are used around the world to control and treat infections in animals and humans, but their overuse and misuse puts their efficacy at risk. Unprecedented movements of people, animals, goods and food worldwide, enable resistant pathogens to populate the planet with ease.

The conference was attended by more than 500 participants, including representatives of OIE’s 182 Member Countries, of international partners (such as FAO, WHO, World Bank, and the United Nations Interagency Coordination Group on AMR), as well as representatives from the meat, dairy, poultry, egg, aquaculture and pharmaceutical industries, civil society and academia.

A prominent theme of the discussions was the need for cross-sector, national level coordination through national action plans to prevent the development and spread of antimicrobial resistance. Conference speakers included Ministers, Deputy Ministers and State Secretaries from countries across the world, including Morocco, Germany, Senegal, Thailand, Japan, Norway, Botswana, Serbia, and Uzbekistan.

“It is only by promoting the responsible and prudent use of antimicrobials that their efficacy can be safeguarded, ensuring that essential medicines that protect both human and animal health can continue to be used.” said Dr Monique Eloit, Director General of OIE. “We have made important progress in this mission today. International Standards on prudent use already exist. We now need to put them into practice at national level to tackle AMR. For this, international collaboration is essential. By working together, countries can discuss challenges, share best practice and make global improvements.”

 

Ebola – Democratic Republic of the Congo

Milestones :: Perspectives

Ebola – Democratic Republic of the Congo

13: Situation report on the Ebola outbreak in North Kivu 
30 October 2018
The Ebola virus disease (EVD) outbreak in North Kivu and Ituri provinces, Democratic Republic of the Congo continues to be closely monitored by the Ministry of Health (MoH), WHO and partners.  Of concern is the increased incidence of confirmed cases reported in the past four weeks, most notably in the city of Beni and communities around Butembo. Security remains the biggest challenge faced by the response teams in Beni and Butembo, undermining the response activities. Continued security incidents severely impact both civilians and frontline workers, forcing suspension of EVD response activities and increasing the risk that the virus will continue to spread. Moreover, with heightened transmission of the virus in outbreak affected areas, the risk of exportation of cases to neighbouring provinces and countries is increased. Neighbouring countries need to be ready in case the outbreak spreads beyond the Democratic Republic of the Congo….

DONs Ebola virus disease – Democratic Republic of the Congo
1 November 2018
[Excerpts]
Vaccination: As of 31 October, 154 vaccination rings have been defined, in addition to 37 rings of health and frontline worker. To date, 25 298 eligible and consented people have been vaccinated, including 8916 health and frontline workers and 6578 children. Overall, vaccination teams have reached an additional 3345 eligible and consenting people in the past week.
Partners
To support the MoH, WHO is working intensively with a wide range of multisectoral and multidisciplinary regional and global partners and stakeholders for EVD response, research and urgent preparedness, including in neighbouring countries. Among the partners are a number of UN agencies and international organizations including: European Civil Protection and Humanitarian Aid Operation (ECHO); International Organization for Migration (IOM); UK Public Health Rapid Support Team; United Nations Children’s Fund (UNICEF); UN High Commission on Refugees (UNHCR); World Bank and regional development banks; World Food Programme (WFP) and UN Humanitarian Air Service (UNHAS); UN mission and UN Department of Safety and Security (UNDSS); Inter-Agency Standing Commission; United Nations Office for the Coordination of Humanitarian Affairs (OCHA); and the United Nations Population Fund (UNFPA); Africa Centres for Disease Control; US CDC; UK Department for International Development (DFID); United States Agency for International Development (USAID); Adeco Federación (ADECO); Association des femmes pour la nutrition à assisse communautaire (AFNAC); Alliance for International Medical Action (ALIMA); CARITAS DRC; CARE International; Centre de promotion socio-sanitaire (CEPROSSAN); Cooperazione Internationale (COOPE); Catholic Organization for Relief and Development Aid (CORDAID/PAP-DRC); International Medical Corps; International Rescue Committee (IRC); Intersos – Organizzatione Umanitaria par l’Emergenza (INTERSOS); MEDAIR; Médecins Sans Frontières (MSF); Oxfam International; Red Cross of the Democratic Republic of Congo, with the support of the International Federation of Red Cross and Red Crescent Societies (IFRC) and International Committee of the Red Cross (ICRC); Samaritan’s Purse; Save the Children (SCI); Global Outbreak Alert and Response Network (GOARN), Emerging and Dangerous Pathogens Laboratory Network (EDPLN), Emerging Disease Clinical Assessment and Response Network (EDCARN), technical networks and operational partners, and the Emergency Medical Team Initiative (EMT). GOARN partners continue to support the response through deployment for response and readiness activities in non-affected provinces and in neighbouring countries and to different levels of WHO.

::::::

Adopting Resolution 2439 (2018), Security Council Condemns Attacks by Armed Groups in Democratic Republic of Congo Jeopardizing Response to Ebola Outbreak
30 October 2018
SC/13559
The Security Council today adopted a resolution condemning attacks by armed groups in the Democratic Republic of the Congo and their role in exacerbating the country’s ongoing Ebola outbreak, while demanding full, safe, immediate and unhindered access for the humanitarian and medical personnel working to save lives and prevent the virus from spreading across the region.

::::::

:: Uganda Finalizes Plans to Vaccinate Front-line Health Workers against Ebola  03 November 2018
:: Zambia heightens its capacity for preventing and responding to the threat of an outbreak of Ebola Virus Disease  02 November 2018
:: WHO enhances Ebola Rapid Response Readiness Capacities in South Sudan  01 November 2018
:: WHO and the Ministry of Health Train Members of the Armed Forces on Ebola Case Management [Uganda]  29 October 2018

 

Emergencies

Emergencies
 
 
POLIO
Public Health Emergency of International Concern (PHEIC)
Polio this week as of 30 October 2018 [GPEI]
:: World Polio Day activities garnered global attention. Partners, donors, and popular public figures around the world brought attention to the cause of polio and the efforts to eradicate polio. A quick overview of some of the World Polio Day highlights
:: The Every Last Child project series was launched by UNICEF, which covers over 30 wide-ranging profiles of governments, front-line workers, and the stakeholders involved in the collective polio eradication efforts across Nigeria, Afghanistan, and Pakistan.
:: Featured on polioeradication.org: Coffee with Polio Experts – Dr Arlene King, Chair of the RCC for the Americas, and GCC Containment Working Group talks to WHO about the importance of safe and secure containment of polioviruses, in places where needed, and the accompanying risk and responsibility that come with retaining the pathogen.
 
Afghanistan – Three new cases of wild poliovirus (WPV1) and four WPV1 positive environmental samples.
  
Democratic Republic of Congo – one new case of circulating vaccine-derived poliovirus type 2 (cVDPV2).
 
Pakistan – No new case of wild poliovirus (WPV1) and seven WPV1 positive environmental samples
 
Nigeria – two new cases of circulating vaccine-derived poliovirus type 2 (cVDPV2).
 
Somalia – four new cVDPV2 positive environmental samples. See country sections below for more details.

::::::
::::::
 
 
Editor’s Note:
WHO has posted a refreshed emergencies page which presents an updated listing of Grade 3,2,1 emergencies as below.
WHO Grade 3 Emergencies  [to 3 Nov 2018 ]
Democratic Republic of the Congo
:: 13: Situation report on the Ebola outbreak in North Kivu  30 October 2018
:: DONs Ebola virus disease – Democratic Republic of the Congo  1 November 2018
[See Milestones above for more detail]

Bangladesh – Rohingya crisis
:: Weekly Situation Report 48 – 25 October 2018
[Excerpt]
…WHO immunization team is planning to start passive surveillance activity of Acute Flaccid Paralysis (AFP), Vaccine Preventable diseases m(VPDs), Congenital rubella syndrome (CRS) and Adverse Event Following Immunization (AEFIs) for early notification and in compliance with the

Ministry of Health (MoH) surveillance program….
 
Nigeria – No new announcements identified
Somalia – No new announcements identified
South Sudan – No new announcements identified
Syrian Arab Republic – No new announcements identified
Yemen – No new announcements identified
::::::
 
WHO Grade 2 Emergencies  [to 3 Nov 2018 ]
Myanmar
:: Weekly Situation Report 48 – 25 October 2018 [see above]
Brazil (in Portugese) – No new announcements identified
Cameroon  – No new announcements identified
Central African Republic  – No new announcements identified
Ethiopia – No new announcements identified
Hurricane Irma and Maria in the Caribbean – No new announcements identified
Iraq – No new announcements identified
occupied Palestinian territory – No new announcements identified
Libya – No new announcements identified
MERS-CoV – No new announcements identified
Niger – No new announcements identified
Sao Tome and Principe Necrotizing Cellulitis (2017) – No new announcements identified
Sudan – No new announcements identified
Ukraine – No new announcements identified
Zimbabwe – No new announcements identified
 

Outbreaks and Emergencies Bulletin, Week 43: 20 – 26 October 2018
The WHO Health Emergencies Programme is currently monitoring 55 events in the region. This week’s edition covers key ongoing events, including:
:: Ebola virus disease outbreak in the Democratic Republic of the Congo
:: Cholera in Cameroon
:: Dengue in Senegal
:: Hepatitis E in Central African Republic.
::::::
 
WHO Grade 1 Emergencies  [to 3 Nov 2018 ]
Afghanistan
Angola (in Portuguese)
Chad
Ethiopia
Kenya
Lao People’s Democratic Republic
Mali
Papua New Guinea
Peru
Tanzania
Tropical Cyclone Gira
Zambia
 
::::::
 
UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Syrian Arab Republic   No new announcements identified.
YemenNo new announcements identified.
::::::
UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
Ethiopia 
:: Ethiopia Humanitarian Bulletin Issue 66 | 15-28 October 2018
 
Somalia  No new announcements identified.
 
::::::
 
“Other Emergencies”
Indonesia: Central Sulawesi Earthquake
:: Central Sulawesi Earthquake & Tsunami: Humanitarian Country Team Situation Report #6 (as of 30 October 2018)
::::::
::::::
 
Editor’s Note:
We will cluster these recent emergencies as below and continue to monitor the WHO webpages for updates and key developments.
 
EBOLA/EVD  [to 3 Nov 2018 ]
http://www.who.int/ebola/en/
[See Milestones above for more detail]
 
MERS-CoV [to 3 Nov 2018 ]
http://who.int/emergencies/mers-cov/en/
No new announcements identified.
 
Yellow Fever  [to 3 Nov 2018 ]
http://www.who.int/csr/disease/yellowfev/en/
No new announcements identified.
 
Zika virus  [to 3 Nov 2018 ]
http://www.who.int/csr/disease/zika/en/
No new announcements identified.
 
::::::
::::::
 
WHO & Regional Offices [to 3 Nov 2018 ]
News Release
29 October 2018
More than 90% of the world’s children breathe toxic air every day
::::::
 
Weekly Epidemiological Record, 2 November 2018, vol. 93, 44 (pp. 589–604)
:: Global programme to eliminate lymphatic filariasis: progress report, 2017
:: Monthly report on dracunculiasis cases, January-September 2018
::::::
 
 
WHO Regional Offices
Selected Press Releases, Announcements

WHO African Region AFRO
Selected Featured News
:: Uganda Finalizes Plans to Vaccinate Front-line Health Workers against Ebola  03 November 2018
:: Zambia heightens its capacity for preventing and responding to the threat of an outbreak of Ebola Virus Disease
02 November 2018
:: WHO enhances Ebola Rapid Response Readiness Capacities in South Sudan  01 November 2018
:: WHO and the Ministry of Health Train Members of the Armed Forces on Ebola Case Management [Uganda]  29 October 2018

WHO Region of the Americas PAHO
:: ‘Health is a right of the people and a responsibility of government,’ says PAHO Director (10/29/2018)
 

WHO South-East Asia Region SEARO
– No new announcement identified
 
 
WHO European Region EURO
:: Simulated poliovirus containment breach helps countries increase biorisk safety and security 01-11-2018
:: Revitalizing primary health care for the 21st century 01-11-2018
 
 
WHO Eastern Mediterranean Region EMRO
– No new announcement identified
 
 
WHO Western Pacific Region
:: 31 October 2018 – Singapore wipes out measles; Australia, Brunei Darussalam and Macao SAR (China) eliminate rubella
:: 30 October 2018  – Joint News Release  <ahref=”http://www.who.int/westernpacific/news/detail/30-10-2018-regional-conference-towards-the-implementation-of-inspire-seven-strategies-for-ending-violence-against-children”>Regional Conference towards the Implementation of INSPIRE: Seven Strategies for Ending Violence against Children
 

CDC/ACIP [to 3 Nov 2018 ]

CDC/ACIP [to 3 Nov 2018 ]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

MMWR News Synopsis for November 2, 2018

Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel

The Advisory Committee on Immunization Practices updated its recommendations on the use of hepatitis A (HepA) vaccine for postexposure prophylaxis and the use of HepA vaccine in infants prior to international travel. Postexposure prophylaxis (PEP) with HepA vaccine or immune globulin (IG) prevents hepatitis A virus infection (HAV) if given within two weeks of exposure. In February 2018, the Advisory Committee on Immunization Practices (ACIP) approved an update of recommendations for use of HepA vaccine for PEP in healthy persons 12 months and older. In addition to HepA vaccine, IG may be administered to persons over 40 years of age, depending on the provider’s risk assessment. HepA vaccine efficacy and safety in infants and the benefits of protection against HAV before international travel were also reviewed. ACIP recommended that HepA vaccine be administered to infants aged 6–11 months traveling outside the United States when protection against HAV is recommended. The updated recommendations specify new guidance for administering PEP for people over 40, and infants for international travel.

 

Announcements

Announcements
 
 
BMGF – Gates Foundation  [to 3 Nov 2018 ]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.
 
 
Bill & Melinda Gates Medical Research Institute    [to 3 Nov 2018 ]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
 
 
CARB-X   [to 3 Nov 2018 ]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
 
 
CEPI – Coalition for Epidemic Preparedness Innovations  [to 3 Nov 2018 ]
http://cepi.net/
No new digest content identified.
 
 
EDCTP    [to 3 Nov 2018 ]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
1 November 2018
EDCTP and Wellcome Trust organise session at ASTMH 2018
EDCTP and the Wellcome Trust organised a session on controlled Human Infection Studies in low- and middle-income countries as a contribution to the ASTMH 2018 programme. The symposium (session 169) takes place on 1 November from 08:00-09:45.
 
 
Emory Vaccine Center    [to 3 Nov 2018 ]
http://www.vaccines.emory.edu/
No new digest content identified.
 
 
European Medicines Agency  [to 3 Nov 2018 ]
http://www.ema.europa.eu/ema/
News and press releases
No new digest content identified.
 
 
European Vaccine Initiative  [to 3 Nov 2018 ]
http://www.euvaccine.eu/news-events
No new digest content identified.
 
 
FDA [to 3 Nov 2018 ]
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
November 01, 2018 –
Jeffrey Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health and Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research on agency’s warning to consumers about genetic tests that claim to predict patients’ responses to specific medications
 
 
Fondation Merieux  [to 3 Nov 2018 ]
http://www.fondation-merieux.org/
Mérieux Foundation co-organized event
Case Management working group / Global Task Force on Cholera Control (GTFCC)
November 5 – 6, 2018 – Les Pensieres Center for Global Health, Veyrier-du-Lac (France)
 
Mérieux Foundation co-organized event
Dengue pre-vaccination screening based on serostatus: rapid tests and implementation strategies
January 14 – 16, 2019 – Les Pensières Center for Global Helath, Veyrier du Lac (France)
 
 
Gavi [to 3 Nov 2018 ]
https://www.gavi.org/
31 October 2018
200,000 girls in Senegal to be protected this year against cervical cancer
… The vaccines, funded by Gavi, the Vaccine Alliance and the Government of Senegal, will reach close to 200,000 nine-year-old girls across the country this year and a further 900,000 girls aged 11-14 years next year. UNICEF, WHO and partners will work on implementation alongside the Senegal Ministry of Health and Social Welfare and the Ministry of National Education….

30 October 2018
Hundreds of thousands of children set to be protected against the leading cause of pneumonia in Haiti
Port-au-Prince, 30 October 2018 – The government of Haiti formally introduced yesterday pneumococcal conjugate vaccine (PCV) into its routine immunisation programme, which will protect hundreds of thousands of Haitian children against pneumococcal disease, the leading cause of pneumonia… With this introduction, as many as 270,000 Haitian children will routinely receive PCV every year – along with pentavalent and rotavirus vaccines which Haiti introduced with support from Gavi, the Vaccine Alliance in 2012 and 2014.
 
 
GHIT Fund   [to 3 Nov 2018 ]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.
 
 
Global Fund  [to 3 Nov 2018 ]
https://www.theglobalfund.org/en/news/
Voices
What’s new about the New Nets Project?
31 October 2018
The Global Fund and Unitaid are each investing US$33 million from 2018 to 2022 to introduce new insecticide-treated nets to fight malaria-carrying mosquitoes.
 
 
Hilleman Laboratories   [to 3 Nov 2018 ]
http://www.hillemanlabs.org/
No new digest content identified.
 
 
Human Vaccines Project   [to 3 Nov 2018 ]
http://www.humanvaccinesproject.org/media/press-releases/
Event
Towards a Universal Influenza Vaccine: Lessons from the Great Influenza Pandemic of 1918 to Now
November 15-16, 2018 I Nashville, TN
The Human Vaccines Project is hosting a scientific summit featuring prominent researchers and thought leaders to discuss cutting-edge influenza research. The 2-day meeting will bring together leading scientists, clinicians and public health specialists including: John Barry, James E. Crowe, Jr., Senator Bill Frist, and Laurie Garrett.  Find a full agenda at:
www.humanvaccinesproject.org/talks/universalinfluenzavaccinesummit

November 01, 2018
Human Vaccines Project Launches New Study to Decode Immune Responses to Influenza
 
 
IAVI  [to 3 Nov 2018 ]
https://www.iavi.org/newsroom
No new digest content identified.
 
 
IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.
 
 
IVAC  [to 3 Nov 2018 ]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
October 2018
Commentary: Pneumonia, Diarrhea, and Measles force Bangladeshi households to make difficult financial decisions when illnesses arise
Few diseases have as much power to cause wide-ranging impact among the population as pneumonia, diarrhea, and measles. These three illnesses can cause long-term disability and can require a significant amount of care. In addition to the pain and the risk of death or disability, people experiencing these illnesses face economic consequences now rising like out-of-pocket expenditures.
 
 
IVI   [to 3 Nov 2018 ]
http://www.ivi.int/
01/11/2018
The GTFCC Marks a Year of Progress Toward Ending Cholera Worldwide
 [See Milestones above for more detail]
 
 
JEE Alliance  [to 3 Nov 2018 ]
https://www.jeealliance.org/
No new digest content identified.
 
 
MSF/Médecins Sans Frontières  [to 3 Nov 2018 ]
http://www.msf.org/
Central African Republic
More than 10,000 seek refuge in Batangafo hospital
2 Nov 2018

Refugees, IDPs and people on the move
“Leaving the country to seek asylum is often the only option for survival”
29 Oct 2018
 
 
NIH  [to 3 Nov 2018 ]
http://www.nih.gov/news-events/news-releases
No new digest content identified.
 
 
PATH  [to 3 Nov 2018 ]
https://www.path.org/media-center/
No new digest content identified.
 
 
Sabin Vaccine Institute  [to 3 Nov 2018 ]
http://www.sabin.org/updates/pressreleases
No new digest content identified.
 
 
UNAIDS [to 3 Nov 2018 ]
http://www.unaids.org/en
2 November 2018
Civil society cooperation network for the Americas and the Caribbean launched

2 November 2018
New data dashboard launched in the Asia and the Pacific region

1 November 2018
New commitment to primary health care

31 October 2018
HIVR4P 2018 highlights new possibilities for HIV prevention

30 October 2018
Training the next generation of Russian doctors on HIV-related stigma and discrimination

29 October 2018
Global HIV prevention targets at risk
 
 
UNICEF  [to 3 Nov 2018 ]
https://www.unicef.org/media/press-releases
Selected Press Releases/Reports/Statements
Press release
In Mexico, children traveling with migrant caravan still in need of protection and support – UNICEF
01/11/2018

Press release
More than 80,000 children returned from Angola to DR Congo in urgent need of humanitarian assistance – UNICEF
30/10/2018

Press release
Global Task Force on Cholera Control marks a year of progress toward ending cholera worldwide
01/11/2018

[See Milestones above for more detail]
 
 
Vaccine Confidence Project  [to 3 Nov 2018 ]
http://www.vaccineconfidence.org/
No new digest content identified.
 
 
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 3 Nov 2018 ]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.
 
 
Wellcome Trust  [to 3 Nov 2018 ]
https://wellcome.ac.uk/news
31 October 2018
How to make sense of the brain’s billions of neurons
A unique global collaboration has produced a new technology that will transform the way we study the brain. Neuropixels allow simultaneous recordings from many hundreds of neurons over multiple brain regions.
 
 
The Wistar Institute   [to 3 Nov 2018 ]
https://www.wistar.org/news/press-releases
No new digest content identified.
 
 
World Organisation for Animal Health (OIE)   [to 3 Nov 2018 ]
http://www.oie.int/en/for-the-media/press-releases/2018/
31/10/18
Ministers agree on international action to address antimicrobial resistance in animals and to safeguard medicines for humans and animals alike
[See Milestones above for more detail]
 
 
::::::
 
 
BIO    [to 3 Nov 2018 ]
https://www.bio.org/insights/press-release
No new digest content identified.
 
 
DCVMN – Developing Country Vaccine Manufacturers Network  [to 3 Nov 2018 ]
http://www.dcvmn.org/
29 October 2018 to 31 October 2018
19th DCVMN Annual General Meeting
Kunming / China
 
 
IFPMA   [to 3 Nov 2018 ]
http://www.ifpma.org/resources/news-releases/
Published on: 29 October 2018
The R&D biopharmaceutical industry supports the Astana Declaration and renewed political commitment towards the importance of primary health care

26 October 2018, Astana – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the body accredited by the United Nations (UN) to represent the R&D biopharmaceutical industry attended Astana at the Global Conference on Primary Health Care on 25-26 October, co-hosted by the Government of Kazakhstan, WHO and UNICEF. R&D biopharmaceutical industry announced its support for the Astana Declaration and welcomed the renewed political commitment towards the importance of primary health care.  The industry body used the occasion to present a number of initiatives that are being pioneered to improve access to treatments and systems that ensure access at the primary care level.

Thomas Cueni, Director General, IFPMA delivered the following message at the Global Conference on Primary Health Care: “The research-based biopharmaceutical industry acknowledges that it needs to do more and do better to bring the fruits of its innovation to all, regardless of economic circumstances. Our industry is much more than a supplier of medicines and vaccines and is pioneering ways to overcome the multiple barriers to access to quality healthcare. Developing more collaborations at the primary health care level will enable healthcare companies to deliver products and services more efficiently and can accelerate progress towards reaching Universal Health Coverage”…
 
 
PhRMA    [to 3 Nov 2018 ]
http://www.phrma.org/press-room
No new digest content identified.

 

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Vaccines and Global Health: The Week in Review has expanded its coverage of new reports, books, research and analysis published independent of the journal channel covered in Journal Watch below. Our interests span immunization and vaccines, as well as global public health, health governance, and associated themes. If you would like to suggest content to be included in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

 

No new digest content identified.

Journal Watch

Journal Watch

   Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

 

Influenza vaccine coverage and predictive factors associated with influenza vaccine uptake among pediatric patients

American Journal of Infection Control
November 2018 Volume 46, Issue 11, p1201-1318
http://www.ajicjournal.org/current

Major Articles
Influenza vaccine coverage and predictive factors associated with influenza vaccine uptake among pediatric patients
Celeste L.Y. Ewig, Ka Ming Tang, Ting Fan Leung, Joyce H.S. You
p1278–1283
Published online: May 23, 2018

Increasing transparency and accountability in national pharmaceutical systems

Bulletin of the World Health Organization
Volume 96, Number 11, November 2018, 729-796
http://www.who.int/bulletin/volumes/96/11/en/

POLICY & PRACTICE
Increasing transparency and accountability in national pharmaceutical systems
– Anne Paschke, Deirdre Dimancesco, Taryn Vian, Jillian C Kohler & Gilles Forte
http://dx.doi.org/10.2471/BLT.17.206516
Abstract
Access to safe, effective, good-quality medicines can be compromised by poor pharmaceutical system governance. This system is particularly vulnerable to inefficiencies and to losses from corruption, because it involves a complex mix of actors with diverse responsibilities. A high level of transparency and accountability is critical for minimizing opportunities for fraud and leakage. In the past decade, the Good Governance for Medicines programme and the Medicines Transparency Alliance focused on improving accountability in the pharmaceutical system and on reducing its vulnerability to corruption by increasing transparency and encouraging participation by a range of stakeholders. Experience with these two programmes revealed that stakeholders interpreted transparency and accountability in a range of different ways. Moreover, programme implementation and progress assessments were complicated by a lack of clarity about what information should be disclosed by governments and about how greater transparency can strengthen accountability for access to medicines. This article provides a conceptual understanding of how transparency can facilitate accountability for better access to medicines. We identified three categories of information as prerequisites for accountability: (i) standards and commitments; (ii) decisions and results; and (iii) consequences and responsive actions. Examples are provided for each. Conceptual clarity and practical examples of the information needed to ensure accountability can help policy-makers identify the actions required to increase transparency and accountability in their pharmaceutical systems. We also discuss factors that can hinder or facilitate the use of information to hold to account those responsible for improving access to medicines.

Best practices in scaling digital health in low and middle income countries

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 3 Nov 2018 ]

Review
Best practices in scaling digital health in low and middle income countries
Healthcare challenges in low and middle income countries (LMICs) have been the focus of many digital initiatives that have aimed to improve both access to healthcare and the quality of healthcare delivery.
Authors: Alain B. Labrique, Christina Wadhwani, Koku Awoonor Williams, Peter Lamptey, Cees Hesp, Rowena Luk and Ann Aerts
Citation: Globalization and Health 2018 14:103
Published on: 3 November 2018

Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 3 Nov 2018 ]

Review
Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems
Access to quality-assured medical products improves health and save lives. However, one third of the world’s population lacks timely access to quality-assured medicines while estimates indicate that at least 1…
Authors: Lukas Roth, Daniel Bempong, Joseph B. Babigumira, Shabir Banoo, Emer Cooke, David Jeffreys, Lombe Kasonde, Hubert G. M. Leufkens, John C. W. Lim, Murray Lumpkin, Gugu Mahlangu, Rosanna W. Peeling, Helen Rees, Margareth Ndomondo-Sigonda, Andy Stergachis, Mike Ward…
Citation: Globalization and Health 2018 14:102
Published on: 1 November 2018

 

 

Rohingya refugees in Bangladesh: the humanitarian response

Humanitarian Exchange Magazine
Number 73,  October 2018
https://odihpn.org/magazine/mental-health-and-psychosocial-support-in-humanitarian-crises/

Rohingya refugees in Bangladesh: the humanitarian response

More than 700,000 Rohingya refugees have arrived in Bangladesh since 25 August 2017 fleeing violence and persecution in Rakhine State, Myanmar. Over a million are sheltering in overcrowded camps without adequate assistance or protection. Stateless in Myanmar and denied refugee status in Bangladesh, the Rohingya have few rights or freedoms. Monsoons and cyclones are causing landslides, destroying shelters and infrastructure and disrupting services.

This edition of Humanitarian Exchange focuses on the humanitarian response to the Rohingya crisis. In the lead article, Mark Bowden outlines the historical, local and national political context in Bangladesh, and its operational implications. Amal de Chickera highlights the links between statelessness and displacement, and the international community’s failure to prioritise human rights in its dealings both with Bangladesh and with Myanmar. Puttanee Kangkun and John Quinley document the persistent persecution and denial of rights the Rohingya have faced for decades. Jeff Crisp reflects on the premature, involuntary and unsafe return of Rohingya refugees to Myanmar in the 1970s and 1990s, and asks whether this could happen again.

Sally Shevach and colleagues explore how the ‘localisation’ agenda has influenced the operational response, and Kerrie Holloway draws on research by the Humanitarian Policy Group to test the common assumption that local actors necessarily have a better understanding of people’s needs. Nasif Rashad Khan and colleagues and Ashish Banik reflect on their experiences of engaging with the international humanitarian response system. Margie Buchanan-Smith and Marian Casey-Maslen discuss evaluation findings relating to communication and community engagement, a theme taken up by Nick Van Praag and Kai Hopkins, who report on a Ground Truth survey on refugees’ perceptions of assistance. Julia Brothwell discusses the British Red Cross/Bangladesh Red Crescent involvement in disaster preparedness and risk reduction during the monsoon season, and Gina Bark, Kate White and Amelie Janon outline the consequences of long-term exclusion from basic healthcare services in increasing vulnerability to preventable diseases. Matthew Wencel and colleagues round off the issue with reflections on data collection coordination and other challenges associated with monitoring large concentrations of refugees.

Reasons for Lack of HPV Vaccine Initiation in NIS-Teen Over Time: Shifting the Focus From Gender and Sexuality to Necessity and Safety

Journal of Adolescent Health
November 2018 Volume 63, Issue 5, p519-662
https://www.jahonline.org/issue/S1054-139X(17)X0026-8

Adolescent Health Briefs
Reasons for Lack of HPV Vaccine Initiation in NIS-Teen Over Time: Shifting the Focus From Gender and Sexuality to Necessity and Safety
Anna Beavis, Melinda Krakow, Kimberly Levinson, Anne F. Rositch
p652–656
Published in issue: November 2018

Enhancing Immunization Rates at Aurora Family Medicine Clinics in Milwaukee, Wisconsin

Journal of Patient-Centered Research and Reviews
Volume 5, Issue 4 (2018)
https://digitalrepository.aurorahealthcare.org/jpcrr/

Patient Self-Management
Enhancing Immunization Rates at Aurora Family Medicine Clinics in Milwaukee, Wisconsin
Zeeshan A. Yacoob, Christopher Cook, Jessica J.F. Kram, Marianne Klumph, Dennis J. Baumgardner, Marisa Stanley, Paul Hunter, and Fabiana Kotovicz

Experiences With Medical Exemptions After a Change in Vaccine Exemption Policy in California

Pediatrics
November 2018, VOLUME 142 / ISSUE 5
http://pediatrics.aappublications.org/content/142/5?current-issue=y

Articles
Experiences With Medical Exemptions After a Change in Vaccine Exemption Policy in California
Salini Mohanty, Alison M. Buttenheim, Caroline M. Joyce, Amanda C. Howa, Daniel Salmon, Saad B. Omer
Pediatrics Nov 2018, 142 (5) e20181051; DOI: 10.1542/peds.2018-1051
On the basis of semistructured interviews with health officers and immunization staff, we described their experiences with SB277, which eliminated nonmedical vaccine exemptions in California.

Vaccination and Risk of Childhood IgA Vasculitis

Pediatrics
November 2018, VOLUME 142 / ISSUE 5
http://pediatrics.aappublications.org/content/142/5?current-issue=y

Vaccination and Risk of Childhood IgA Vasculitis
Maryam Piram, Solange Gonzalez Chiappe, Fouad Madhi, Tim Ulinski, Alfred Mahr
Pediatrics Nov 2018, 142 (5) e20180841; DOI: 10.1542/peds.2018-0841
In this study, we discuss the risk of developing pediatric IgAV (Henoch–Schönlein purpura) in the 3 months after vaccinations.